The Schall Law Firm Reminds Investors of Class Action Lawsuit Against Moderna, Inc.
Investor Alert
LOS ANGELES, Aug. 21, 2024 (GLOBE NEWSWIRE) — The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Moderna, Inc. (“Moderna” or “the Company”) (NASDAQ: MRNA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company’s securities between January 18, 2023 and June 25, 2024, inclusive (the “Class Period”), are encouraged to contact the firm before October 8, 2024.
The Allegations
The lawsuit alleges that Moderna made false and/or misleading statements and/or failed to disclose that: (1) the Company was experiencing a significant decline in COVID-19 vaccine sales due to vaccine hesitancy and increasing competition; (2) Moderna’s vaccine distribution growth was likely to decline; and (3) as a result of the foregoing, Moderna’s positive statements about its business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you are an investor who suffered a loss during the Class Period, you have until October 8, 2024, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
How This Affects You
As an investor in Moderna, Inc., this class action lawsuit may directly impact your investment in the company. If the allegations are proven to be true, the value of Moderna’s stock may decrease, resulting in potential financial losses for shareholders. It is important to stay informed about the developments of this lawsuit and consider your options moving forward.
How This Affects the World
The outcome of this class action lawsuit against Moderna, Inc. could have broader implications for the pharmaceutical industry and the perception of vaccine manufacturers. If the allegations of false or misleading statements are substantiated, it may erode trust in the company and impact public confidence in COVID-19 vaccines. This could have ripple effects on vaccination efforts and public health strategies globally.
Conclusion
In conclusion, the class action lawsuit against Moderna, Inc. highlights the importance of transparency and accountability in the pharmaceutical industry. Investors should monitor the developments of this case closely and consider their options to protect their investments. The implications of this lawsuit extend beyond financial markets and may have lasting effects on public health initiatives worldwide.
